Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TMLI During Conditioning for HLA-Haploidentical HCT in Myelodysplasia or Acute Leukemia
NCT02446964Phase 1Completed
- Sponsor
- City of Hope
- Start
- Jun 2015
- Primary completion
- May 2025
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS), sponsored by City of Hope. Primary endpoints: Incidence of dose-limiting toxicity up to 100 days and Maximum tolerated dose of TMLI. Started Jun 2015; status: completed.
02
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02446964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02446964.